Log In Sign up
The largest database of trusted experimental protocols

Anti human cd34 apc 8g12

Manufactured by BD
Visit Supplier
Sourced in United States

Anti-human CD34–APC (8G12) is a laboratory reagent used for the detection and analysis of CD34 positive cells. It consists of a monoclonal antibody specific for the human CD34 antigen, conjugated to the fluorescent dye Allophycocyanin (APC). This product is intended for research use only.

Automatically generated - may contain errors

Lab products found in correlation

Cytofix cytoperm fixation permeabilization kit, by BD (2 mentions) Live dead fixable aqua dead cell stain, by Thermo Fisher Scientific (2 mentions) Rpa t8, by BioLegend (2 mentions) Hcd56, by BioLegend (2 mentions) Rpa t4, by BioLegend (2 mentions) Streptavidin apc cy7, by BioLegend (2 mentions) Cd11b icrf44, by BioLegend (2 mentions) Clone rpa 2, by BioLegend (2 mentions) Cd7 124 1d1, by Thermo Fisher Scientific (2 mentions) Cd10 sn5c, by Thermo Fisher Scientific (2 mentions) Cd20 2h7, by Thermo Fisher Scientific (2 mentions) Anti cd38 pe cy7 hit2, by BioLegend (2 mentions) Anti cd90 fitc 5e10, by BD (2 mentions) Anti cd45ra pb mem 56, by Thermo Fisher Scientific (2 mentions) Anti cd123 pe 7g3, by BD (2 mentions) Anti human ki 67 bv605 antibody, by BioLegend (2 mentions) Cd14 hcd14, by BioLegend (2 mentions) Cd19 hib19, by BioLegend (2 mentions) Lsrii flow cytometer, by BD (2 mentions) Facsaria 2, by BD (2 mentions)

Spelling variants of this product

Anti-CD34 (78 citations) CD34-APC (76 citations) Anti-CD34-APC (23 citations) Anti-human CD34-APC (7 citations) Human CD34-APC (3 citations) CD34-APC (8G12) (2 citations)

4 protocols using anti human cd34 apc 8g12

1

Flow Cytometric Immunophenotyping of Hematopoietic Progenitor Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were thawed at 37 °C, washed with sterile PBS and incubated with biotinylated anti-human lineage antibodies directed against CD2 (clone RPA-2.10, BioLegend), CD3 (HIT3a, 300304, BioLegend), CD4 (RPA-T4, BioLegend), CD7 (124-1D1, eBioscience), CD8a (RPA-T8, BioLegend), CD10 (SN5c, eBioscience), CD11b (ICRF44, BioLegend), CD14 (HCD14, BioLegend), CD19 (HIB19, BioLegend), CD20 (2H7, eBioscience), CD56 (HCD56, BioLegend) and GPA (HIR2, BioLegend) and LIVE/DEAD Fixable Aqua Dead Cell Stain (L-34957, Life Technologies). For gating on hematopoietic progenitor cells, this was followed by secondary staining with anti-human CD34–APC (8G12, BD Biosciences), anti-CD38–PE/Cy7 (HIT2, BioLegend), anti-CD90–FITC (5E10, BD Biosciences), anti-CD45RA-PB (MEM-56, Thermo Fisher Scientific), anti-CD123–PE (7G3, BD Biosciences) and streptavidin-APC/Cy7 (BioLegend). Intracellular staining with anti-human Ki-67–BV605 antibody (BioLegend) was performed using the BD Cytofix/Cytoperm Fixation/Permeabilization kit. Samples were run on an LSR II flow cytometer (BD Biosciences), and recorded events were analyzed with FlowJo 10 software (BD). Individual fluorescence-minus-one controls were used to determine gating. HSCs were identified as lineage−CD34+CD38−CD45RAloCD90+ cells, CMPs as lineage−CD34+CD38intCD45 RA−CD123int cells and GMPs as lineage−CD34+CD38intCD45RA+CD123int cells.
Rohde D., Vandoorne K., Lee I.H., Grune J., Zhang S., McAlpine C.S., Schloss M.J., Nayar R., Courties G., Frodermann V., Wojtkiewicz G., Honold L., Chen Q., Schmidt S., Iwamoto Y., Sun Y., Cremer S., Hoyer F.F., Iborra-Egea O., Muñoz-Guijosa C., Ji F., Zhou B., Adams R.H., Wythe J.D., Hidalgo J., Watanabe H., Jung Y., van der Laan A.M., Piek J.J., Kfoury Y., Désogère P.A., Vinegoni C., Dutta P., Sadreyev R.I., Caravan P., Bayes-Genis A., Libby P., Scadden D.T., Lin C.P., Naxerova K., Swirski F.K, & Nahrendorf M. (2021). Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease. Nature cardiovascular research, 1(1), 28-44.
+ Open protocol
+ Expand
2

Flow Cytometric Immunophenotyping of Hematopoietic Progenitor Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were thawed at 37 °C, washed with sterile PBS and incubated with biotinylated anti-human lineage antibodies directed against CD2 (clone RPA-2.10, BioLegend), CD3 (HIT3a, 300304, BioLegend), CD4 (RPA-T4, BioLegend), CD7 (124-1D1, eBioscience), CD8a (RPA-T8, BioLegend), CD10 (SN5c, eBioscience), CD11b (ICRF44, BioLegend), CD14 (HCD14, BioLegend), CD19 (HIB19, BioLegend), CD20 (2H7, eBioscience), CD56 (HCD56, BioLegend) and GPA (HIR2, BioLegend) and LIVE/DEAD Fixable Aqua Dead Cell Stain (L-34957, Life Technologies). For gating on hematopoietic progenitor cells, this was followed by secondary staining with anti-human CD34–APC (8G12, BD Biosciences), anti-CD38–PE/Cy7 (HIT2, BioLegend), anti-CD90–FITC (5E10, BD Biosciences), anti-CD45RA-PB (MEM-56, Thermo Fisher Scientific), anti-CD123–PE (7G3, BD Biosciences) and streptavidin-APC/Cy7 (BioLegend). Intracellular staining with anti-human Ki-67–BV605 antibody (BioLegend) was performed using the BD Cytofix/Cytoperm Fixation/Permeabilization kit. Samples were run on an LSR II flow cytometer (BD Biosciences), and recorded events were analyzed with FlowJo 10 software (BD). Individual fluorescence-minus-one controls were used to determine gating. HSCs were identified as lineage−CD34+CD38−CD45RAloCD90+ cells, CMPs as lineage−CD34+CD38intCD45 RA−CD123int cells and GMPs as lineage−CD34+CD38intCD45RA+CD123int cells.
Rohde D., Vandoorne K., Lee I.H., Grune J., Zhang S., McAlpine C.S., Schloss M.J., Nayar R., Courties G., Frodermann V., Wojtkiewicz G., Honold L., Chen Q., Schmidt S., Iwamoto Y., Sun Y., Cremer S., Hoyer F.F., Iborra-Egea O., Muñoz-Guijosa C., Ji F., Zhou B., Adams R.H., Wythe J.D., Hidalgo J., Watanabe H., Jung Y., van der Laan A.M., Piek J.J., Kfoury Y., Désogère P.A., Vinegoni C., Dutta P., Sadreyev R.I., Caravan P., Bayes-Genis A., Libby P., Scadden D.T., Lin C.P., Naxerova K., Swirski F.K, & Nahrendorf M. (2021). Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease. Nature cardiovascular research, 1(1), 28-44.
+ Open protocol
+ Expand
3

Immunophenotypic Characterization of AML Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cryopreserved primary AML cells and engrafted PDX BM cells were thawed and their phenotypes were analyzed using FACSAria2 (BD Biosciences, San Jose, CA, USA) with anti-mouse CD45-APC/Cy7 (30-F11, dilution 1:100), anti-human CD45-PerCP/Cy5.5 (HI30, dilution 1:100) (BioLegend, San Diego, CA, USA), anti-human CD45-PE (HI30, dilution 1:100), anti-human CD34-APC (8G12, dilution 1:100), anti-human CD38-PE/Cy7 (HB7, dilution 1:100), and anti-human CD3-APC (UCHT1, dilution 1:100) antibodies (BD Biosciences, San Jose, CA, USA). Flow cytometry data were collected using FACSAria2 and FACSDiva software v8.0.1 (BD Biosciences, San Jose, CA, USA) and analyzed using FlowJo software v8.8.7 (BD Biosciences, San Jose, CA, USA). The gating strategy is detailed in Supplementary Fig. 6.
Kawashima N., Ishikawa Y., Kim J.H., Ushijima Y., Akashi A., Yamaguchi Y., Hattori H., Nakashima M., Ikeno S., Kihara R., Nishiyama T., Morishita T., Watamoto K., Ozawa Y., Kitamura K, & Kiyoi H. (2022). Comparison of clonal architecture between primary and immunodeficient mouse-engrafted acute myeloid leukemia cells. Nature Communications, 13, 1624.
+ Open protocol
+ Expand
4

Lentiviral Transduction of CD34+ Cord Blood Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary human CD34-enriched cord blood was transduced with lentivirus (pLVX EF1α-IRES-zsGreen; Clontech) overnight, and sorted for GFP expression using a FACSAria II (Becton-Dickinson). For progenitor media assay, cells were, washed and incubated in HPGM medium (Lonza) supplemented with FLT3L, thrombopoietin and stem cell factor (SCF). The cytokines were all purchased from Peprotech and used at 20 ng/ml. 6 days post-culture, differentiation of GFP-positive cells was assessed by flow cytometry using anti-human CD34-APC (8G12) and CD38-PE-Cy7 (HB7) (BD Biosciences). For myeloid differentiation assay, cells were cultured in Myelocult H5100 (Stem Cell Technologies) with 20-µg/mL each of IL-3, SCF, FLT3L, and GM-CSF (Peprotech) for 6 days. Myeloid differentiation was assessed by flow cytometry using anti-human CD33-PE (WM53) and CD14-APC-Cy7 (MφP9) (BD Biosciences). For erythroid differentiation assay, cells were cultured in Stemspan II with erythroid expansion kit (Stemcell Technologies) for 6 days. Erythroid differentiation was assessed by flow cytometry using anti-human GPA-PE (CD235a) (HIR2) and CD71-PE-Cy7 (OKT9) (BD Biosciences).
Mazumdar C., Shen Y., Xavy S., Zhao F., Reinisch A., Li R., Corces-Zimmerman M.R., Flynn R.A., Buenrostro J.D., Chan S.M., Thomas D., Koenig J.L., Hong W.J., Chang H.Y, & Majeti R. (2015). Leukemia-associated cohesin mutants dominantly enforce stem cell programs and impair human hematopoietic progenitor differentiation. Cell stem cell, 17(6), 675-688.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!